Chan Raymond Tsz-Tong
Hong Kong Pacific Centre, Tsim Sha Tsui, Kowloon, Hong Kong.
Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9. doi: 10.1111/ajco.12853.
Non-small cell lung cancers (NSCLC) harboring the uncommon epidermal growth factor receptor (EGFR) exon 20 insertion mutations are generally thought to be unresponsive to EGFR-tyrosine kinase inhibitor (TKI) therapy. Presented here is a case of stage IV NSCLC harboring an uncommon EGFR exon 20 insertion mutation that was maintained at minimal progressive disease for 54 months, with 36 months on the second-generation TKI afatinib. Contrary to the existing literature, the patient in this case demonstrated a long, durable response to the EGFR-TKI, which was exhibited by a long survival endpoint. This suggests that stability in clinical symptoms might be sufficient to warrant continuation of therapy.
携带罕见表皮生长因子受体（EGFR）外显子20插入突变的非小细胞肺癌（NSCLC）通常被认为对EGFR酪氨酸激酶抑制剂（TKI）治疗无反应。本文介绍了一例IV期NSCLC病例，该病例携带罕见的EGFR外显子20插入突变，疾病进展缓慢，维持了54个月，其中36个月使用第二代TKI阿法替尼治疗。与现有文献相反，该病例中的患者对EGFR-TKI表现出长期、持久的反应，表现为较长的生存终点。这表明临床症状的稳定可能足以保证继续治疗。
